Our Biotechnology Intellectual Property team provides legal insight on intellectual property strategy, patent prosecution and transactional IP due diligence for Life Sciences companies of all sizes. We provide strategic counseling for clients in the areas of large molecule therapeutics (e.g., antibodies and peptides), small molecule therapeutics, cellular therapeutics, molecular diagnostics, biotechnology and alternative foods/meat substitutes.
Our practitioners routinely handle domestic and foreign prosecution for patent portfolios of all sizes, providing sophisticated counseling and portfolio management, as well as representation in post-grant proceedings at the U.S. Patent and Trademark Office (USPTO), litigation in federal courts and cases before the U.S. International Trade Commission (ITC).
The high volume of our filings over the years has also given us particularly strong skills and insight into helping clients with patent reviews and reexaminations, reissues and other contested post-grant proceedings before the USPTO, including inter partes reviews and covered business method patent reviews.
We have devised IP strategies that encompass not only patents, but also data rights and the strategic use of trade secrets to provide overlapping end-to-end protection for proprietary products and services and partnering agreements to leverage or monetize such technology and IP rights.
Depth of Industry Knowledge − We understand the Biotechnology industry inside and out – from where it’s been, to where it is, to where it’s going next. We have managed or worked in the following areas:
- Monoclonal Antibodies, Antibody Drug Conjugates (ADCs), Bispecific T-cell Engagers (TCEs) and CAR-T Cells
- Genomic Analysis and Gene Editing
- Computational Biology
- Molecular Diagnostics
- Synthetic Oligosaccharides
- AI/Machine Learning as applied to the Life Sciences Sector
- Tumor Profiling Assays and Interpretive Software
- Bioprocess Manufacturing